guidance

What to Expect for AstraZeneca in Fiscal 2018
What to Expect for AstraZeneca in Fiscal 2018
Market Realist
AstraZeneca
guidance
generics
Crestor
Japan
Europe
Flag link:
Medtronic releases long term guidance
Medtronic releases long term guidance
Mass Device
Medtronic
devices
guidance
earnings
Flag link:
By How Much Did Eli Lilly Revise Guidance for 2016?
By How Much Did Eli Lilly Revise Guidance for 2016?
Market Realist
Eli Lilly
earnings
guidance
Flag link:
Allergan Raises Profit Forecast as Valeant Pursues Bid
Allergan Raises Profit Forecast as Valeant Pursues Bid
Bloomberg
Allergan
Valeant Pharmaceuticals
guidance
Flag link:
AbbVie Raises Outlook on Strong Performance Amid Shire Offer
AbbVie Raises Outlook on Strong Performance Amid Shire Offer
Bloomberg
AbbVie
Shire
M&A
guidance
Flag link:
Bayer Raises Drug Sales Forecast as Quarterly Profit Lags
Bayer Raises Drug Sales Forecast as Quarterly Profit Lags
Bloomberg
Bayer
guidance
earnings
Flag link:
Merck Raises 2013 Profit Forecast on Speed of Cost Cuts
Merck Raises 2013 Profit Forecast on Speed of Cost Cuts
Bloomberg
Merck
guidance
Flag link:
Sanofi Profit Forecast Eases Concern After Setbacks
Sanofi Profit Forecast Eases Concern After Setbacks
Bloomberg
Sanofi
guidance
Flag link:
Novartis Raises 2013 Forecast on Lack of Diovan Generic
Novartis Raises 2013 Forecast on Lack of Diovan Generic
Bloomberg
Novartis
guidance
Diovan
Flag link:
Johnson & Johnson expect to incur $100M charge to net income in Q1
Johnson & Johnson expect to incur $100M charge to net income in Q1
The Fly on the Wall
JNJ
guidance
Flag link:
Strong 1Q from Myriad, Guidance Up
Strong 1Q from Myriad, Guidance Up
Yahoo/Zacks.com
earnings
guidance
Myriad Genetics
Flag link:
Novo hikes forecast on 62% jump in Victoza sales
Novo hikes forecast on 62% jump in Victoza sales
Fierce Pharma
Novo Nordisk
guidance
Flag link:
Novo raises targets on Victoza, insulin demand
Novo raises targets on Victoza, insulin demand
Yahoo/Reuters
Victoza
guidance
Novo Nordisk
insulin
Flag link:
Lilly raises 2012 net profit forecast
Lilly raises 2012 net profit forecast
Reuters
Lilly
guidance
Flag link:
Actelion Raises 2012 Forecast On Reduced First-Half Costs
Actelion Raises 2012 Forecast On Reduced First-Half Costs
Bloomberg
Actelion
guidance
Flag link:
PDL BioPharma expects 2 percent revenue growth on better sales of Herceptin, Lucentis, Tysabri
PDL BioPharma expects 2 percent revenue growth on better sales of Herceptin, Lucentis, Tysabri
Yahoo/AP
PDL Biopharma
guidance
Herceptin
Biogen Idec
Lucentis
Tysabri
Flag link:
Forest Labs cuts outlook on Lexapro discounts
Forest Labs cuts outlook on Lexapro discounts
Yahoo/AP
Forest Labs
Lexapro
guidance
Flag link:
Teva Issues 2012 Outlook
Teva Issues 2012 Outlook
Yahoo/Zacks
Teva Pharmaceuticals
guidance
Flag link:
Teva Pharm cuts 2012 sales, profit outlook
Teva Pharm cuts 2012 sales, profit outlook
Reuters
Teva Pharmaceuticals
guidance
Flag link:
Warner Chilcott cuts full-year forecast
Warner Chilcott cuts full-year forecast
Reuters
earnings
guidance
Warner Chilcott
Flag link:

Pages